Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type I in breast cancer patients

British Journal of Cancer

Volumn 88, Issue 1, 2003, Pages 102-108

  Hansen, S ^a   Overgaard, J ^b   Rose, C ^a,c   Knoop, Ann ^a   Laenkholm A V ^a   Andersen, J ^b   Sorensen F B ^b   Andreasen, P A ^d  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

Breast neoplasms; Neovascularization; Prognosis; Survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; TAMOXIFEN; TUMOR EXTRACT; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; DEATH; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR VASCULARIZATION;

ADULT; AGED; BREAST NEOPLASMS; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037434421     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600662     Document Type: Article

References (37)

1. Andersen KW, Mouridsen HT (1988) Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol 27: 627-647
2. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40
3. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
4. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noel A (2001) The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152: 777-784
5. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4: 923-928
6. Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377
7. Christensen L, Simonsen ACW, Heegaard CW, Moestrup SK, Andersen JA, Andreasen P (1996) Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha-2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66: 441-452
8. Cox DR (1972) Regression models and life tables. J Roy Star Soc 34: 187-220
9. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noel A, Foidart JM (2002) The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16: 147-154
10. Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618
11. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N (1999) Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71: 130-135
12. Fischerman K, Mouridsen HT (1988) Danish Breast Cancer Cooperative Group (DBCG). Structure and results of the organization. Acta Oncol 27: 593-596
13. Folkman J (1971) Tumor anglogenesis: therapeutic implications. N Engl J Med 285: 1182-1186
14. Folkman J (1995) Tumor angiogenesis. In The Molecular Basis of Cancer, Mendelsohn J, Howley PM, Israel MA, Liotta LA (eds) pp 206-232. Philadelphia: W.B. Saunders.
15. Fox SB (1997) Tumour angiogenesis and prognosis. Histopathology 30: 294-301
16. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL (1995) Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177: 275-283
17. Fox SB, Taylor M, Grondahl-Hansen J, Kakolyris S, Gatter KC, Harris AL (2001) Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. J Pathol 195: 236-243
18. Hansen S, Grabau DA, Rose C, Bak M, Sørensen FB (1998) Angiogenesis in breast cancer. A comparative study of the observer variability of methods for determining microvessel density. Lab Invest 78: 1563-1573
19. Hansen S, Grabau DA, Sørensen FB, Bak M, Vach W, Rose C (2000a) Vascular grading of angiogenesis: prognostic significance in breast cancer. Br J Cancer 82: 339-347
20. Hansen S, Grabau DA, Sørensen FB, Bak M, Vach W, Rose C (2000b) The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 6: 139-146
21. Harbeck N, Graeff H, Hofler H, Brunner N, Schmitt M (1998) Plasminogen activator system in breast cancer tissue and blood: clinical relevance and methodological considerations. J Tumor Marker Oncol 13: 19-35
22. Harrell Jr FE, Lee KL, Matchar DB, Reichert TA (1985) Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 69: 1071-1077
23. Hildenbrand R, Dilger I, Horlin A, Stutte HJ (1995) Urokinase and macrophages in tumour angiogenesis. Br J Cancer 72: 818-823
24. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93: 913-920
25. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
26. Knoop A, Andreasen PA, Andersen JA, Hansen S, Lænkhulm A-V, Simonsen ACW, Andersen J, Overgaard J, Rose C (1998) Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77: 932-940
27. Lambert V, Munaut C, Noel A, Frankenne F, Bajou K, Gerard R, Carmeliet P, Defresne MP, Foidart JM, Rakic JM (2001) Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 15: 1021-1027
28. Look MP, Foekens JA (1999) Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS 107: 150-159
29. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128
30. Mazar AP, Henkin J, Goldfarb RH (1999) The urokinase plasminogen activator system in cancer: implication for tumor angiogenesis and metastasis. Angiogenesis 3: 15-32
31. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276: 33964-33968
32. Mignatti P, Rifkin DB (1996) Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49: 117-137
33. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR (1996) A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49: 1373-1379
34. Pepper MS, Montesano R, Mandriota SJ, Orci L, Vassalli JD (1996) Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 49: 138-162
35. Rose C, Hansen S, Grabau DA, Bak M, Vach W, Sørensen FB (2000) Prognostic value of angiogenesis by microvessel density in breast cancer patients. Proc Am Soc Clin Oncol 2580:
36. Scharff RW, Torloni H (1998) Histological typing of breast tumours. International histological classification of tumours, No.2. Geneva
37. Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69: 979-985